Electronic Supplementary Material

Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients With Open-Angle Glaucoma or Ocular Hypertension

Felipe A. Medeiros, MD, PhD,1 Arsham Sheybani, MD,2 Manjool M. Shah, MD,3 Marcos Rivas, PhD,4 Zhanying Bai, MS,5 Erica Werts, PharmD,4 Iqbal IK Ahmed, MD,6 E Randy Craven, MD4

1Department of Ophthalmology, Duke University, Durham, North Carolina, USA; 2Department of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA; 3Kellogg Eye Center, Ann Arbor, Michigan, USA; 4Allergan, an AbbVie company, Irvine, California, USA; 5Allergan, an AbbVie company, Irvine, California, USA, at the time of this work; 6Department of Ophthalmology, University of Toronto, Mississauga, Ontario, Canada

Corresponding author: Felipe A. Medeiros, MD, PhD; Duke Eye Center, 2351 Erwin Rd, Durham, NC, USA 27705; E-mail: felipe.medeiros@duke.edu
Table S1. Baseline Demographics of the 10-µg Bimatoprost Implant Treatment Group in the Phase 1/2 Study

| Characteristic                              | 10-µg Bimatoprost Implant (N=21) |
|---------------------------------------------|----------------------------------|
| Age, mean (SD), years                       | 65.4 (6.6)                       |
| Range                                       | 52–77                            |
| Male, n (%)                                 | 12 (57.1)                        |
| Race/ethnicity, n (%)                       |                                  |
| White                                       | 15 (71.4)                        |
| Black or African American                   | 4 (19.0)                         |
| Hispanic                                    | 1 (4.8)                          |
| Asian                                       | 1 (4.8)                          |
| Diagnosis, n (%)                            |                                  |
| POAG (both eyes)                            | 21 (100)                         |
| Lens status, n (%)                          |                                  |
| Phakic (both eyes)                          | 14 (66.7)                        |
| Pseudophakic (both eyes)                    | 7 (33.3)                         |
| IOP, mean (SD), mmHg                        |                                  |
| Hour 0 (8 AM) (study eye)                   | 24.5 (2.1)                       |
| Hour 2 (10 AM) (study eye)                  | 23.6 (1.9)                       |
| Hour 0 (8 AM) (fellow eye)                  | 24.1 (2.1)                       |
| Hour 2 (10 AM) (fellow eye)                 | 23.1 (2.4)                       |
| CECD, mean (SD), µm                         |                                  |
| Study eye                                   | 2691.3 (175.7)                   |
| Fellow eye                                  | 2650.4 (201.9)                   |

CECD = central corneal endothelial cell density; IOP = intraocular pressure; POAG = primary open-angle glaucoma; SD = standard deviation.